Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
Gluskin Sheff's David Rosenberg reinforces his recession forecast following the Federal Reserve's September meeting.Futures Nowread more
"This would be the most profound violation of the presidential oath of office certainly during this presidency," House Intelligence Chair Adam Schiff said.Politicsread more
A 58% majority of registered voters express unease about voting for Trump, but slightly more say the same about Joe Biden and Bernie Sanders, while Elizabeth Warren fares only...Politicsread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
Valeant Pharmaceuticals CEO Joseph Papa on Wednesday told CNBC he is "never going to say never" to selling core assets like Bausch & Lomb.
"Would we have to look at something if someone came forward with something? Of course we would, because we're a public company and we have over $30 billion of debt," he said in an interview with "Closing Bell."
However, those core assets — like dermatology and eye care — are "critically important" to the future of the company, he added.
Therefore, the company will focus on selling non-core assets, which he said could yield proceeds up to $8 billion.
The embattled drugmaker has seen its stock plunge about 90 percent since its record high last August after questions about its steep drug increases and unorthodox business practices. Papa took the reins of the embattled company in May.
Valeant is being investigated for its pricing practices and patient assistance program by the Securities and Exchange Commission as well as the U.S. Attorney's offices in Massachusetts and New York. It is also facing shareholder lawsuits.
Papa said the company has hired a new general counsel and said, "We're going to work very closely with all the investigations and resolve them expeditiously."
He also noted the company will be faced with potential legal bills in the future, which will take some time to resolve.
"In the meantime, we're going to continue to grow … our earnings for the company and we're also going to look at these asset sales. So we think we can work our way through this in a very practical way," said Papa.
Meanwhile, activist investor Bill Ackman has been a "wonderful source of information" and "incredibly helpful," Papa said.
The CEO of Pershing Square Capital Management joined the Valeant board in March. He is one of 10 new board members, Papa said, that bring a great range of experience from both the investor and pharmaceutical worlds.
— Reuters contributed to this report.